Differential Second Primary Malignancy Occurrence After Breast Cancer According to HER2 Status: A Population-Based Study.
Xiao-Yi LinXin LinYingzi LiYuchen ZhangJiali LinGuochun ZhangPublished in: International journal of general medicine (2021)
It is demonstrated that HER2+ BC patients had lower SPM incidence, which was remarkable for second BC and lung cancer.